Cargando…
HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME)
PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen that was recently found to be expressed by malignant melanocytic lesions but not by benign ones, thus resulting useful in this diagnostic field. PRAME could also be expressed by some normal tissues and nonmelanocytic...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575561/ https://www.ncbi.nlm.nih.gov/pubmed/34508017 http://dx.doi.org/10.1097/PAI.0000000000000972 |
_version_ | 1784811336061943808 |
---|---|
author | Grillini, Marco Ricci, Costantino Pino, Vincenzo Pedrini, Silvia Fiorentino, Michelangelo Corti, Barbara |
author_facet | Grillini, Marco Ricci, Costantino Pino, Vincenzo Pedrini, Silvia Fiorentino, Michelangelo Corti, Barbara |
author_sort | Grillini, Marco |
collection | PubMed |
description | PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen that was recently found to be expressed by malignant melanocytic lesions but not by benign ones, thus resulting useful in this diagnostic field. PRAME could also be expressed by some normal tissues and nonmelanocytic tumors, suggesting as caution should be adopted to use PRAME as a “pan-melanoma” marker for the differential diagnosis with other malignant tumors. Until now, PRAME expression was exclusively investigated through single staining with a monoclonal antibody targeting PRAME and with double staining for Melan A/PRAME found to be useful in specific diagnostic sets. Herein, we studied the expression of PRAME in 40 melanocytic lesions and 23 nonmelanocytic ones using PRAME, Melan A/PRAME, and novel double staining for HMB45/PRAME. Although our results need to be validated, they support the adoption of HMB45/PRAME, alone or in combination with PRAME and Melan A/PRAME, as a helpful marker in the diagnosis of melanocytic neoplasms with a high concordance rate between primary melanoma and corresponding metastases. |
format | Online Article Text |
id | pubmed-9575561 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-95755612022-10-19 HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) Grillini, Marco Ricci, Costantino Pino, Vincenzo Pedrini, Silvia Fiorentino, Michelangelo Corti, Barbara Appl Immunohistochem Mol Morphol Technical Article PRAME (PReferentially expressed Antigen in MElanoma) is a tumor-associated antigen that was recently found to be expressed by malignant melanocytic lesions but not by benign ones, thus resulting useful in this diagnostic field. PRAME could also be expressed by some normal tissues and nonmelanocytic tumors, suggesting as caution should be adopted to use PRAME as a “pan-melanoma” marker for the differential diagnosis with other malignant tumors. Until now, PRAME expression was exclusively investigated through single staining with a monoclonal antibody targeting PRAME and with double staining for Melan A/PRAME found to be useful in specific diagnostic sets. Herein, we studied the expression of PRAME in 40 melanocytic lesions and 23 nonmelanocytic ones using PRAME, Melan A/PRAME, and novel double staining for HMB45/PRAME. Although our results need to be validated, they support the adoption of HMB45/PRAME, alone or in combination with PRAME and Melan A/PRAME, as a helpful marker in the diagnosis of melanocytic neoplasms with a high concordance rate between primary melanoma and corresponding metastases. Lippincott Williams & Wilkins 2022-01 2021-09-10 /pmc/articles/PMC9575561/ /pubmed/34508017 http://dx.doi.org/10.1097/PAI.0000000000000972 Text en Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/) (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) |
spellingShingle | Technical Article Grillini, Marco Ricci, Costantino Pino, Vincenzo Pedrini, Silvia Fiorentino, Michelangelo Corti, Barbara HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) |
title | HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) |
title_full | HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) |
title_fullStr | HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) |
title_full_unstemmed | HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) |
title_short | HMB45/PRAME, a Novel Double Staining for the Diagnosis of Melanocytic Neoplasms: Technical Aspects, Results, and Comparison With Other Commercially Available Staining (PRAME and Melan A/PRAME) |
title_sort | hmb45/prame, a novel double staining for the diagnosis of melanocytic neoplasms: technical aspects, results, and comparison with other commercially available staining (prame and melan a/prame) |
topic | Technical Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9575561/ https://www.ncbi.nlm.nih.gov/pubmed/34508017 http://dx.doi.org/10.1097/PAI.0000000000000972 |
work_keys_str_mv | AT grillinimarco hmb45prameanoveldoublestainingforthediagnosisofmelanocyticneoplasmstechnicalaspectsresultsandcomparisonwithothercommerciallyavailablestainingprameandmelanaprame AT riccicostantino hmb45prameanoveldoublestainingforthediagnosisofmelanocyticneoplasmstechnicalaspectsresultsandcomparisonwithothercommerciallyavailablestainingprameandmelanaprame AT pinovincenzo hmb45prameanoveldoublestainingforthediagnosisofmelanocyticneoplasmstechnicalaspectsresultsandcomparisonwithothercommerciallyavailablestainingprameandmelanaprame AT pedrinisilvia hmb45prameanoveldoublestainingforthediagnosisofmelanocyticneoplasmstechnicalaspectsresultsandcomparisonwithothercommerciallyavailablestainingprameandmelanaprame AT fiorentinomichelangelo hmb45prameanoveldoublestainingforthediagnosisofmelanocyticneoplasmstechnicalaspectsresultsandcomparisonwithothercommerciallyavailablestainingprameandmelanaprame AT cortibarbara hmb45prameanoveldoublestainingforthediagnosisofmelanocyticneoplasmstechnicalaspectsresultsandcomparisonwithothercommerciallyavailablestainingprameandmelanaprame |